Pharmacologic and Clinical Testing of a D1 Agonist for Cognitive Enhancement in Neuropsychiatric Disorders
Status:
Completed
Trial end date:
2013-11-01
Target enrollment:
Participant gender:
Summary
The investigators propose to recruit individuals with schizophrenia who are symptomatically
stable and already taking medications to participate in this study. The investigators will
recruit 90 individuals with schizophrenia and randomize them to low and high doses of
DAR-0100A, as well as to placebo. The investigators will have them stay in the hospital for
several weeks and receive up to 10 doses of DAR-0100A. The investigators will also test their
cognition before and after receiving DAR-0100A to see if DAR-0100A is helpful and perform MRI
scans before and after taking the medication to see which areas of the brain are activated
when DAR-0100A is administered. These tests will be very important because they will help the
investigators determine whether the D1 receptor is a good treatment target for schizophrenia
and whether more research and resources should be devoted to finding medications that target
this system.
Patients with schizophrenia will be free of other medical, psychiatric and neurological
disorders including alcohol and substance dependence, and will be able to understand the
nature of the study and to provide informed consent.